Chimeric Therapeutics Ltd

Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company, focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its diversified portfolio includes first-in-class autologous CAR T cell therapies and allogeneic natural killer (NK) cell therapies. Its assets are being developed across multiple different disease areas in oncology with four clinical stage programs. Its pipeline includes CHM CDH17, CHM CLTX and CHM CORE NK platform. CHM CDH17 is a third-generation CDH17 CAR T, which is in phase I/II clinical trial in gastrointestinal and neuroendocrine tumors. CHM CORE-NK is a clinically validated NK cell platform in phase IB clinical trials investigating CORE-NK in combination regimens. CHM CLTX is a novel CAR-T therapy developed for the treatment of patients with solid tumors. CLTX CAR T is in phase IB clinical trial in recurrent/progressive glioblastoma. It is also building a Cell therapy portfolio.